The BTF welcomes the decision of the Scottish Medicines Consortium (SMC) to recommend the use of lenvatinib within NHS Scotland. 

Lenvatinib is used for patients with advanced, progressive thyroid cancer which is not responsive to radioactive iodine treatment. The trial results with the drug in this situation were very promising and came on the back of positive trial data with another anti-cancer drug called sorafenib. Although these drugs are not suitable for all patients with advanced thyroid cancer it is extremely encoouraging that after decades of limited progress in the treatment of thyroid cancer, we now have two drugs which can be offered to patients with progressive disease.

For further information about the decision please go to the SMC website.